Investors who lost money on GSK plc(GSK) should contact The Gross Law Firm about pending Class Action - GSK

Core Viewpoint - GSK plc is facing allegations related to misleading statements regarding the withdrawal of Zantac from the market, with claims that the company was aware of the source of NDMA for nearly 40 years before the product's removal [1]. Group 1: Allegations and Legal Context - The class period for the allegations against GSK spans from February 5, 2020, to August 14, 2022 [1]. - Defendants allegedly misrepresented to investors that GSK removed Zantac based on available information and correspondence with regulators, while also claiming that there was no evidence linking ranitidine therapy to cancer [1]. - The complaint asserts that GSK's representations were materially false or misleading, as the company had prior knowledge of the NDMA source [1]. Group 2: Shareholder Actions and Deadlines - Shareholders who purchased GSK shares during the specified class period are encouraged to register for the class action, with a deadline set for April 7, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3: Firm's Mission and Commitment - The Gross Law Firm aims to protect the rights of investors affected by deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [3]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that inflated the company's stock value [3].